David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

Gut microbiota composition may influence the efficacy and safety of chemo-immunotherapy in advanced non-small cell lung cancer. Read now.

The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...

Updated results from the CheckMate 274 trial provide support for adjuvant nivolumab as a standard of care for muscle-invasive bladder cancer, according to Matthew Milowsky, MD.

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...